Stocks · News reference

Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

Aug 11, 2026, 4:57 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 11, 2026, 11:33 AMSEC EDGAR
8-K filing — Autolus Therapeutics plc (AUTL)
Filed: 2026-08-11 AccNo: 0001730463-26-000119 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
AUTL
BenzingaAug 11, 2026, 11:01 AMBenzinga Newsdesk
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
Read original at benzinga
AUTL
BenzingaAug 11, 2026, 11:00 AMBenzinga Newsdesk
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses of $(0.18) per share
Read original at benzinga
AUTL